Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.

Scientific reports - 31 Dec 2020

Rendo Veronica, Kundu Snehangshu, Rameika Natallia, Ljungström Viktor, Svensson Richard, Palin Kimmo, Aaltonen Lauri, Stoimenov Ivaylo, Sjöblom Tobias

Abstract excerpt

Therapies targeting somatic bystander genetic events represent a new avenue for cancer treatment. We recently identified a subset of colorectal cancer (CRC) patients who are heterozygous for a wild-type and a low activity allele (NAT2*6) but lack the wild-type allele in their tumors due to loss of heterozygosity (LOH) at 8p22. These tumors were sensitive to treatment with a cytotoxic substrate of NAT2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Colorectal Neoplasms

Share to Enzyme Inhibitors

Share to High-Throughput Nucleotide Sequencing

Share to Molecular Targeted Therapy

Share to Single Molecule Imaging

Source

Open in PubMed Open full text

Identifiers

PMID: 33384440
DOI: 10.1038/s41598-020-80288-z
PMCID: PMC7775439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.PMID 33384440Read ↗

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.Semantic proximity Read ↗

Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity.Semantic proximity Read ↗

N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions.Semantic proximity Read ↗

Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.Semantic proximity Read ↗

Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparibSemantic proximity Read ↗

Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma.Semantic proximity Read ↗

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype.Semantic proximity Read ↗

Novel NAT2 haplotyping using allele-specific sequencing.Semantic proximity Read ↗

NAT2 gene polymorphism and sporadic colorectal cancer. Prevalence, tumor stage and prognosis. A preliminary study in 70 patients.Semantic proximity Read ↗

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.Semantic proximity Read ↗

Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A.Semantic proximity Read ↗

Screening and characterizing human NAT2 variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.